Baylor College of Medicine
Houston, Texas, 77030, United States
Location status: Recruiting
NCT Number: NCT04740580
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
Interested in participating?
Request Info55 year–85 year
All sexes
Interventional
Early Phase 1
Houston, Texas, 77030, United States
Location status: Recruiting
Glutathione (GSH) deficiency, oxidative stress, mitochondrial dysfunction, insulin resistance and inflammation are linked to Alzheimer's disease (AD). In prior studies, investigators have shown that GSH deficiency contributes to mitochondrial impairment and oxidative stress, and that GSH deficiency can be corrected by supplementing its precursors glycine and cysteine (provided as N-acetylcysteine, NAC), with the combination termed GlyNAC.
This randomized clinical trial will evaluate the effect of GlyNAC vs. alanine placebo supplementation provided for 24-weeks to patients with AD, and measure changes in cognition, GSH concentrations, oxidative stress, brain glucose uptake, brain inflammation and insulin resistance.
Participants who are positive for a beta-amyloid PET scan and meeting cognitive screening criteria will be recruited, and enrolled only after meeting eligibility criteria. Before beginning study supplementation they will undergo imaging studies (MRI, FDG-PET and TSPO-PET scans), and only the FDG- and TSPO-PET scans will be repeated after completing 24-weeks of nutrient supplementation. Cognitive measurements, metabolic and mitochondrial measurements (as described below) will be done before supplementation, and after 12-weeks and 24-weeks of completing supplementation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
The placebo arm will supplement Alanine
Time frame: Day 0 of supplementation, and 12-weeks and 24-weeks after starting supplementation
Measured using ADAS-Cog testing
Time frame: Done before supplementation and 24-weeks after starting supplementation
Measured using brain FDG-PET scan
Time frame: Done before supplementation and 24-weeks after starting supplementation
Done using brain TSPO-PET scan
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured using the ADCS-ADL scale
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured using indirect calorimetry in the fasted and post-glucose fed state
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured using UPLC
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured as plasma concentrations of TBARS and malondialdehyde
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured as plasma concentration of isoprostanes
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured as plasma concentrations of IL6, TNFa
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured as plasma concentrations of sICAM1, sVCAM1, E-selectin
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured using an ELISA kit
Time frame: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation
Measured using the Oroboros high-resolution respirometer
Contact information is provided by the study sponsor or research team.
Baylor College of Medicine
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06014424
Alzheimer Disease, Brain Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT06847321
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Phoenix, Arizona, United States
View Trial DetailsNCT06937229
Aberrant Motor Behavior in Dementia, Agitation
Chandler, Arizona, United States
View Trial DetailsNCT06862960
Alzheimer Disease, Brain Diseases
Fuzhou, Fujian, China
View Trial Details